Summary

The global tumour-induced osteomalacia market is projected to be valued at US$ 154 Mn in 2025, with an expected rise to US$ 190 Mn by 2032, expanding at a CAGR of 3.05% during the forecast period from 2025 to 2032. Tumour-induced osteomalacia (TIO) is a rare condition resulting from phosphaturic mesenchymal tumors that disrupt phosphate metabolism. Though uncommon, its debilitating impact and the need for targeted therapies have pushed it into the spotlight in rare disease research. As awareness grows and diagnostic tools advance, the market is anticipated to witness steady growth, particularly in specialized healthcare settings.

Tumour-Induced Osteomalacia Market – Report Scope:

The tumour-induced osteomalacia market encompasses a range of treatment and diagnostic solutions aimed at managing this rare metabolic bone disorder. Common therapies include phosphate and vitamin D supplements, with Burosumab emerging as a revolutionary treatment targeting the underlying hormonal imbalance caused by FGF-23 overexpression. Diagnostic techniques such as MRI, CT scans, and FGF-23 assays play a pivotal role in accurate identification. The market's scope is broadening with increased research activity, new drug approvals, and enhanced focus on rare disease management across both developed and emerging regions.


Market Growth Drivers:

The growth of the tumour-induced osteomalacia market is primarily driven by increasing clinical awareness and improvements in diagnostic capabilities. Enhanced imaging technologies and biochemical markers such as FGF-23 have made earlier and more accurate diagnosis possible. The approval and clinical adoption of Burosumab, a targeted therapy, have further improved treatment outcomes, stimulating demand. Additionally, global initiatives focused on rare disease recognition and funding are encouraging pharmaceutical players to invest in niche treatment development, supporting the market’s growth trajectory.

Market Restraints:

Despite its promising outlook, the market for tumour-induced osteomalacia faces several barriers. The rarity of the condition results in low patient numbers, which limits large-scale clinical trials and impacts commercial returns for drug developers. High treatment costs, particularly of biologics like Burosumab, can hinder patient access, especially in lower-income countries. Furthermore, due to overlapping symptoms with other bone-related conditions such as osteoporosis or vitamin D deficiency, TIO is often misdiagnosed or diagnosed late, resulting in delayed treatment initiation and higher disease burden.

Market Opportunities:

Emerging opportunities in the tumour-induced osteomalacia market lie in technological advancements and increased research focus on rare metabolic disorders. Progress in molecular diagnostics, imaging modalities, and AI-assisted tumor localization techniques can significantly improve disease detection. Additionally, expanding healthcare access in Asia Pacific and Latin America, along with orphan drug development incentives, offer lucrative avenues for market expansion. Companies that collaborate with research institutions and invest in awareness programs are well-positioned to gain market share in this highly specialized field.


Regional Outlook:

North America is expected to dominate the global tumour-induced osteomalacia market, backed by early adoption of novel therapies, advanced healthcare infrastructure, and supportive reimbursement policies. Europe also holds a considerable share due to growing awareness of rare diseases and strong regulatory support for orphan drugs. Meanwhile, Asia Pacific is likely to witness the fastest growth during the forecast period, driven by increasing investments in rare disease diagnosis and treatment, particularly in countries like India, China, and Japan. Latin America and the Middle East & Africa offer potential in the long term as healthcare systems improve and access to diagnostics expands.


Leading Companies:

Key players operating in the global tumour-induced osteomalacia market include:

• Ultragenyx Pharmaceutical Inc.

• Dishman Carbogen Amcis Ltd.

• Teva Pharmaceuticals

• Glenmark Pharmaceuticals

• Wockhardt Ltd

• FDC Limited

• Lupin Pharmaceuticals

• Zydus Cadila Healthcare Ltd.

• Intas Pharmaceuticals Ltd

• Macleods Pharmaceuticals

• G.C. Chemie Pharmie Ltd

• Santiago Life Sciences

These companies are focused on rare disease drug development, strategic collaborations, and global expansion strategies to strengthen their presence in this emerging market.


Market Segmentation:

By Treatment:

• Drugs and Supplements

o Burosumab -twza

o Cinarcalcet

o Calcium

o Active Vitamin D (Calcitriol/α-calcitriol)

o Phosphorus

• Surgery

By Diagnosis:

• Laboratories

o Elevated Blood Fibroblast Growth Factor 23 (FGF-23)

o Serum Calcium, PTH, Vitamin D

o Hyperphosphaturia (Secondary Effects of FGF-23)

o Hypophosphatemia (Secondary Effects of FGF-23)

• Imaging

o Bone Scan

o Magnetic Resonance Imaging (MRI)

o Computed Tomography (CT Scans)

• Differential Diagnosis

o Vitamin D Metabolism and Deficiency

o Osteoporosis

o Renal Osteodystrophy

o Others

By End User:

• Hospitals

• Specialty Clinics

• Others

By Region:

• North America

• Latin America

• Europe

• Asia Pacific

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Tumour-Induced Osteomalacia Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Tumour-Induced Osteomalacia Market Outlook, 2018 – 2031
3.1. Global Tumour-Induced Osteomalacia Market Outlook, by Treatment, Value (US$ Mn), 2018 – 2031
3.1.1. Key Highlights
3.1.1.1. Drugs and Supplements
3.1.1.1.1. Burosumab -twza
3.1.1.1.2. Cinarcalcet
3.1.1.1.3. Calcium
3.1.1.1.4. Active Vitamin D (Calcitriol/α-calcitriol)
3.1.1.1.5. Phosphorus
3.1.1.2. Surgery
3.2. Global Tumour-Induced Osteomalacia Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
3.2.1. Key Highlights
3.2.1.1. Hospitals
3.2.1.2. Specialty Clinics
3.2.1.3. Others
3.3. Global Tumour-Induced Osteomalacia Market Outlook, by Diagnosis, Value (US$ Mn), 2018 – 2031
3.3.1. Key Highlights
3.3.1.1. Laboratories
3.3.1.1.1. Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
3.3.1.1.2. Serum Calcium, PTH, Vitamin D
3.3.1.1.3. Hyperphosphaturia (Secondary Effects of FDF-23)
3.3.1.1.4. Hypophosphatemia (Secondary Effects of FDF-23)
3.3.1.2. Bone Scan
3.3.1.2.1. Magnetic Resonance Imaging (MRI)
3.3.1.2.2. Computed Tomography (CT scans)
3.3.1.3. Differential Diagnosis
3.3.1.3.1. Vitamin D Metabolism and Deficiency
3.3.1.3.2. Osteoporosis
3.3.1.3.3. Renal Osteodystrophy
3.3.1.3.4. Others
3.4. Global Tumour-Induced Osteomalacia Market Outlook, by Region, Value (US$ Mn), 2018 – 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Tumour-Induced Osteomalacia Market Outlook, 2018 – 2031
4.1. North America Tumour-Induced Osteomalacia Market Outlook, by Treatment, Value (US$ Mn), 2018 – 2031
4.1.1. Key Highlights
4.1.1.1. Drugs and Supplements
4.1.1.1.1. Burosumab -twza
4.1.1.1.2. Cinarcalcet
4.1.1.1.3. Calcium
4.1.1.1.4. Active Vitamin D (Calcitriol/α-calcitriol)
4.1.1.1.5. Phosphorus
4.1.1.2. Surgery
4.2. North America Tumour-Induced Osteomalacia Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
4.2.1. Key Highlights
4.2.1.1. Hospitals
4.2.1.2. Specialty Clinics
4.2.1.3. Others
4.3. North America Tumour-Induced Osteomalacia Market Outlook, by Diagnosis, Value (US$ Mn), 2018 – 2031
4.3.1. Key Highlights
4.3.1.1. Laboratories
4.3.1.1.1. Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
4.3.1.1.2. Serum Calcium, PTH, Vitamin D
4.3.1.1.3. Hyperphosphaturia (Secondary Effects of FDF-23)
4.3.1.1.4. Hypophosphatemia (Secondary Effects of FDF-23)
4.3.1.2. Bone Scan
4.3.1.2.1. Magnetic Resonance Imaging (MRI)
4.3.1.2.2. Computed Tomography (CT scans)
4.3.1.3. Differential Diagnosis
4.3.1.3.1. Vitamin D Metabolism and Deficiency
4.3.1.3.2. Osteoporosis
4.3.1.3.3. Renal Osteodystrophy
4.3.1.4. Others
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Tumour-Induced Osteomalacia Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
4.4.1.2. U.S. Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
4.4.1.3. U.S. Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
4.4.1.4. Canada Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
4.4.1.5. Canada Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
4.4.1.6. Canada Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Tumour-Induced Osteomalacia Market Outlook, 2018 – 2031
5.1. Europe Tumour-Induced Osteomalacia Market Outlook, by Treatment, Value (US$ Mn), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Drugs and Supplements
5.1.1.1.1. Burosumab -twza
5.1.1.1.2. Cinarcalcet
5.1.1.1.3. Calcium
5.1.1.1.4. Active Vitamin D (Calcitriol/α-calcitriol)
5.1.1.1.5. Phosphorus
5.1.1.2. Surgery
5.2. Europe Tumour-Induced Osteomalacia Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Hospitals
5.2.1.2. Specialty Clinics
5.2.1.3. Others
5.3. Europe Tumour-Induced Osteomalacia Market Outlook, by Diagnosis, Value (US$ Mn), 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Laboratories
5.3.1.1.1. Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
5.3.1.1.2. Serum Calcium, PTH, Vitamin D
5.3.1.1.3. Hyperphosphaturia (Secondary Effects of FDF-23)
5.3.1.1.4. Hypophosphatemia (Secondary Effects of FDF-23)
5.3.1.2. Bone Scan
5.3.1.2.1. Magnetic Resonance Imaging (MRI)
5.3.1.2.2. Computed Tomography (CT scans)
5.3.1.3. Differential Diagnosis
5.3.1.3.1. Vitamin D Metabolism and Deficiency
5.3.1.3.2. Osteoporosis
5.3.1.3.3. Renal Osteodystrophy
5.3.1.4. Others
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Tumour-Induced Osteomalacia Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
5.4.1. Key Highlights
5.4.1.1. Germany Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
5.4.1.2. Germany Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.3. Germany Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
5.4.1.4. U.K. Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
5.4.1.5. U.K. Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.6. U.K. Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
5.4.1.7. France Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
5.4.1.8. France Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.9. France Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
5.4.1.10. Italy Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
5.4.1.11. Italy Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.12. Italy Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
5.4.1.13. Turkey Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
5.4.1.14. Turkey Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.15. Turkey Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
5.4.1.16. Russia Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
5.4.1.17. Russia Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.18. Russia Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
5.4.1.19. Rest of Europe Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
5.4.1.20. Rest of Europe Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
5.4.1.21. Rest of Europe Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Tumour-Induced Osteomalacia Market Outlook, 2018 – 2031
6.1. Asia Pacific Tumour-Induced Osteomalacia Market Outlook, by Treatment, Value (US$ Mn), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Drugs and Supplements
6.1.1.1.1. Burosumab -twza
6.1.1.1.2. Cinarcalcet
6.1.1.1.3. Calcium
6.1.1.1.4. Active Vitamin D (Calcitriol/α-calcitriol)
6.1.1.1.5. Phosphorus
6.1.1.2. Surgery
6.2. Asia Pacific Tumour-Induced Osteomalacia Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Hospitals
6.2.1.2. Specialty Clinics
6.2.1.3. Others
6.3. Asia Pacific Tumour-Induced Osteomalacia Market Outlook, by Diagnosis, Value (US$ Mn), 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. Laboratories
6.3.1.1.1. Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
6.3.1.1.2. Serum Calcium, PTH, Vitamin D
6.3.1.1.3. Hyperphosphaturia (Secondary Effects of FDF-23)
6.3.1.1.4. Hypophosphatemia (Secondary Effects of FDF-23)
6.3.1.2. Bone Scan
6.3.1.2.1. Magnetic Resonance Imaging (MRI)
6.3.1.2.2. Computed Tomography (CT scans)
6.3.1.3. Differential Diagnosis
6.3.1.3.1. Vitamin D Metabolism and Deficiency
6.3.1.3.2. Osteoporosis
6.3.1.3.3. Renal Osteodystrophy
6.3.1.4. Others
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Tumour-Induced Osteomalacia Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
6.4.1. Key Highlights
6.4.1.1. China Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
6.4.1.2. China Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
6.4.1.3. China Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
6.4.1.4. Japan Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
6.4.1.5. Japan Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
6.4.1.6. Japan Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
6.4.1.7. South Korea Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
6.4.1.8. South Korea Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
6.4.1.9. South Korea Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
6.4.1.10. India Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
6.4.1.11. India Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
6.4.1.12. India Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
6.4.1.13. Southeast Asia Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
6.4.1.14. Southeast Asia Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
6.4.1.15. Southeast Asia Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
6.4.1.16. Rest of Asia Pacific Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
6.4.1.17. Rest of Asia Pacific Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
6.4.1.18. Rest of Asia Pacific Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Tumour-Induced Osteomalacia Market Outlook, 2018 – 2031
7.1. Latin America Tumour-Induced Osteomalacia Market Outlook, by Treatment, Value (US$ Mn), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Drugs and Supplements
7.1.1.1.1. Burosumab -twza
7.1.1.1.2. Cinarcalcet
7.1.1.1.3. Calcium
7.1.1.1.4. Active Vitamin D (Calcitriol/α-calcitriol)
7.1.1.1.5. Phosphorus
7.1.1.2. Surgery
7.2. Latin America Tumour-Induced Osteomalacia Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
7.2.1.1. Hospitals
7.2.1.2. Specialty Clinics
7.2.1.3. Others
7.3. Latin America Tumour-Induced Osteomalacia Market Outlook, by Diagnosis, Value (US$ Mn), 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Laboratories
7.3.1.1.1. Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
7.3.1.1.2. Serum Calcium, PTH, Vitamin D
7.3.1.1.3. Hyperphosphaturia (Secondary Effects of FDF-23)
7.3.1.1.4. Hypophosphatemia (Secondary Effects of FDF-23)
7.3.1.2. Bone Scan
7.3.1.2.1. Magnetic Resonance Imaging (MRI)
7.3.1.2.2. Computed Tomography (CT scans)
7.3.1.3. Differential Diagnosis
7.3.1.3.1. Vitamin D Metabolism and Deficiency
7.3.1.3.2. Osteoporosis
7.3.1.3.3. Renal Osteodystrophy
7.3.1.4. Others
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Tumour-Induced Osteomalacia Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
7.4.1.2. Brazil Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
7.4.1.3. Brazil Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
7.4.1.4. Mexico Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
7.4.1.5. Mexico Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
7.4.1.6. Mexico Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
7.4.1.7. Argentina Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
7.4.1.8. Argentina Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
7.4.1.9. Argentina Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
7.4.1.10. Rest of Latin America Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
7.4.1.11. Rest of Latin America Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
7.4.1.12. Rest of Latin America Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Tumour-Induced Osteomalacia Market Outlook, 2018 – 2031
8.1. Middle East & Africa Tumour-Induced Osteomalacia Market Outlook, by Treatment, Value (US$ Mn), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Drugs and Supplements
8.1.1.1.1. Burosumab -twza
8.1.1.1.2. Cinarcalcet
8.1.1.1.3. Calcium
8.1.1.1.4. Active Vitamin D (Calcitriol/α-calcitriol)
8.1.1.1.5. Phosphorus
8.1.1.2. Surgery
8.2. Middle East & Africa Tumour-Induced Osteomalacia Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Hospitals
8.2.1.2. Specialty Clinics
8.2.1.3. Others
8.3. Middle East & Africa Tumour-Induced Osteomalacia Market Outlook, by Diagnosis, Value (US$ Mn), 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. Laboratories
8.3.1.1.1. Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
8.3.1.1.2. Serum Calcium, PTH, Vitamin D
8.3.1.1.3. Hyperphosphaturia (Secondary Effects of FDF-23)
8.3.1.1.4. Hypophosphatemia (Secondary Effects of FDF-23)
8.3.1.2. Bone Scan
8.3.1.2.1. Magnetic Resonance Imaging (MRI)
8.3.1.2.2. Computed Tomography (CT scans)
8.3.1.3. Differential Diagnosis
8.3.1.3.1. Vitamin D Metabolism and Deficiency
8.3.1.3.2. Osteoporosis
8.3.1.3.3. Renal Osteodystrophy
8.3.1.4. Others
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Tumour-Induced Osteomalacia Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
8.4.1. Key Highlights
8.4.1.1. GCC Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
8.4.1.2. GCC Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
8.4.1.3. GCC Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
8.4.1.4. South Africa Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
8.4.1.5. South Africa Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
8.4.1.6. South Africa Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
8.4.1.7. Egypt Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
8.4.1.8. Egypt Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
8.4.1.9. Egypt Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
8.4.1.10. Nigeria Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
8.4.1.11. Nigeria Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
8.4.1.12. Nigeria Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
8.4.1.13. Rest of Middle East & Africa Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 – 2031
8.4.1.14. Rest of Middle East & Africa Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 – 2031
8.4.1.15. Rest of Middle East & Africa Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 – 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Distribution Channel vs by End User Heat map
9.2. Manufacturer vs by End User Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Ultragenyx Pharmaceutical Inc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Dishman Carbogen Amcis Ltd.
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Teva Pharmaceuticals
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Glenmark Pharmaceuticals
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Wockhardt Ltd
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. FDC Limited
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Lupin Pharmaceuticals
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Intas Pharmaceuticals Ltd
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Zydus Cadila Healthcare Ltd.
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Macleods Pharmaceuticals
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations